|Nivolumab versus everolimus in advanced renal-cell carcinoma|
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
|Pembrolizumab as second-line therapy for advanced urothelial carcinoma|
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
|Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma|
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...
New England Journal of Medicine 378 (14), 1277-1290, 2018
|Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial|
R Pettengell, H Gurney, JA Radford, DP Deakin, R James, PM Wilkinson, ...
|Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.|
Journal of Clinical Oncology 14 (9), 2590-2611, 1996
|Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma|
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
|Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer|
JF Bishop, J Dewar, GC Toner, J Smith, MHN Tattersall, IN Olver, ...
Journal of Clinical Oncology 17 (8), 2355-2355, 1999
|How to calculate the dose of chemotherapy|
British journal of cancer 86 (8), 1297-1302, 2002
|Evidence for therapeutic drug monitoring of targeted anticancer therapies|
B Gao, S Yeap, A Clements, B Balakrishnar, M Wong, H Gurney
Journal of clinical oncology 30 (32), 4017-4025, 2012
|Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype|
H Gurney, M Wong, RL Balleine, LP Rivory, AJ McLachlan, JM Hoskins, ...
Clinical Pharmacology & Therapeutics 82 (1), 33-40, 2007
|Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.|
HP Gurney, S Ackland, V Gebski, G Farrell
Journal of clinical oncology 16 (7), 2299-2304, 1998
|Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer|
NA Spry, L Kristjanson, B Hooton, L Hayden, G Neerhut, H Gurney, ...
European Journal of Cancer 42 (8), 1083-1092, 2006
|Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia|
H Gurney, V Grill, TJ Martin
The Lancet 341 (8861), 1611-1613, 1993
|CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma|
B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ...
European urology 72 (6), 962-971, 2017
|Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025|
B Escudier, RJ Motzer, P Sharma, J Wagstaff, ER Plimack, HJ Hammers, ...
European urology 72 (3), 368-376, 2017
|CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy|
M Wong, RL Balleine, M Collins, C Liddle, CL Clarke, H Gurney
Clinical Pharmacology & Therapeutics 75 (6), 529-538, 2004
|Moving towards dose individualization of tyrosine kinase inhibitors|
HJ Klümpen, CF Samer, RHJ Mathijssen, JHM Schellens, H Gurney
Cancer treatment reviews 37 (4), 251-260, 2011
|Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer|
HM Lin, L Castillo, KL Mahon, K Chiam, BY Lee, Q Nguyen, MJ Boyer, ...
British journal of cancer 110 (10), 2462-2471, 2014
|Primary treatment of the prostate improves local palliation in men who ultimately develop castrate‐resistant prostate cancer|
ACM Won, H Gurney, G Marx, P De Souza, MI Patel
BJU international 112 (4), E250-E255, 2013
|Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …|
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019